An infant participating in Novartis' Zolgensma trial has died, raising questions ahead of an expected FDA decision next month for this one-and-done treatment for spinal muscular atrophy. Here's what you should know. Also, why investors should ignore Intuitive Surgical's first quarter earnings miss and buy shares on sale.

Check out more of our content here:

• TMF's podcast portal
• YouTube
• Twitter
• Join Our Motley Fool Podcast Facebook Group
• LinkedIn
• StockUp, The Motley Fool's weekly email newsletter